Does this optic neuritis patient have neuromyelitis optica? An approach to optic neuritis in the context of neuromyelitis optica

Optic neuritis is a common presentation of demyelinating disease, most often associated with multiple sclerosis, and typically associated with a relatively good recovery and prognosis. However, when optic neuritis is the heralding event of neuromyelitis optica (NMO), it is much more likely to be the start of a devastating and disabling chronic disease with a reduced lifespan. Early recognition of NMO is the best chance a patient has of avoiding life-altering disability, as relapse prevention is essentially disability prevention because this disease, unlike MS, does not really have a progressive component. The following review was written to assist the clinician, particularly the ophthalmologist, in assessing optic neuritis in evaluating and recognizing the potential NMO patient.

[1]  R. Zivadinov,et al.  Conventional and Advanced Imaging in Neuromyelitis Optica , 2014, American Journal of Neuroradiology.

[2]  P. Calabresi,et al.  Differentiating NMO and MS-Associated Optic Neuritis by MRI (S63.002) , 2014 .

[3]  A. Falini,et al.  Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica , 2014, Annals of neurology.

[4]  Y. Lim,et al.  First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis , 2014, Neurological Sciences.

[5]  David H. Miller,et al.  Optic neuritis , 2014, The Lancet Neurology.

[6]  F. Costello,et al.  An approach to optic neuritis: the initial presentation , 2013 .

[7]  S. Jarius,et al.  Aquaporin‐4 Antibodies (NMO‐IgG) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature , 2013, Brain pathology.

[8]  Fiona Costello,et al.  The Afferent Visual Pathway: Designing a Structural-Functional Paradigm of Multiple Sclerosis , 2013, ISRN neurology.

[9]  Su-Hyun Kim,et al.  A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. , 2013, JAMA neurology.

[10]  Axel Petzold,et al.  Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis , 2013, PloS one.

[11]  B. Weinshenker,et al.  Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study , 2013, The Lancet Neurology.

[12]  G. Plant,et al.  Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis: A Novel Magnetic Resonance Imaging Scoring System , 2013, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[13]  R. Gold,et al.  Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. , 2013, JAMA neurology.

[14]  H. Hartung,et al.  Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. , 2013, JAMA neurology.

[15]  M. Alvarenga,et al.  Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica , 2013, Multiple sclerosis.

[16]  Su-Hyun Kim,et al.  Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and Effects on Circulating Anti-Aquaporin-4 Antibody Levels , 2013, Journal of clinical neurology.

[17]  Su-Hyun Kim,et al.  Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder , 2012, Multiple sclerosis international.

[18]  S. Olindo,et al.  Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  M. Hutchinson,et al.  Does natalizumab therapy worsen neuromyelitis optica? , 2012, Neurology.

[20]  D. Wingerchuk,et al.  Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. , 2012, Archives of neurology.

[21]  M. Gordon,et al.  Magnetic Resonance Imaging of Optic Neuritis in Patients With Neuromyelitis Optica Versus Multiple Sclerosis , 2012, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[22]  M. Salvetti,et al.  Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature , 2012, Multiple sclerosis.

[23]  M. Papadopoulos,et al.  Aquaporin 4 and neuromyelitis optica , 2012, The Lancet Neurology.

[24]  Jacqueline A Palace,et al.  Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete? , 2012, Neuroradiology.

[25]  F. Paul,et al.  Failure of natalizumab to prevent relapses in neuromyelitis optica. , 2012, Archives of neurology.

[26]  P. Cabre,et al.  Plasma Exchange in Severe Attacks of Neuromyelitis Optica , 2012, Multiple sclerosis international.

[27]  Shiv Saidha,et al.  Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. , 2012, Brain : a journal of neurology.

[28]  F. Paul,et al.  Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients , 2012, Journal of Neuroinflammation.

[29]  Su-Hyun Kim,et al.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. , 2011, Archives of neurology.

[30]  B. Lam,et al.  Impact of rituximab on relapse rate and disability in neuromyelitis optica , 2011, Multiple sclerosis.

[31]  B. Weinshenker,et al.  Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica , 2011, Neurology.

[32]  K. Kyvik,et al.  A population-based study of neuromyelitis optica in Caucasians , 2011, Neurology.

[33]  Su-Hyun Kim,et al.  Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. , 2011, Archives of neurology.

[34]  C. Gieger,et al.  Variant screening of the coding regions of MEIS1 in patients with restless legs syndrome , 2011, Neurology.

[35]  S. Weigand,et al.  Neuromyelitis optica unique area postrema lesions , 2011, Neurology.

[36]  R. Raininko,et al.  Bilateral and recurrent optic neuritis in multiple sclerosis , 2011, Acta neurologica Scandinavica.

[37]  Y. Itoyama,et al.  Therapeutic efficacy of interferon β-1b in Japanese patients with optic-spinal multiple sclerosis. , 2011, The Tohoku journal of experimental medicine.

[38]  Axel Petzold,et al.  Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis , 2010, The Lancet Neurology.

[39]  Jacqueline A Palace,et al.  Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. , 2010, Archives of neurology.

[40]  Brigitte Wildemann,et al.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance , 2010, Nature Reviews Neurology.

[41]  T. Nakazawa,et al.  Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[42]  D. Wingerchuk Neuromyelitis optica: Effect of gender , 2009, Journal of the Neurological Sciences.

[43]  B. Weinshenker,et al.  Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. , 2009, Archives of neurology.

[44]  P. Calabresi,et al.  Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies , 2009, Neurology.

[45]  K. Trinkaus,et al.  Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis , 2009, Neurology.

[46]  B. Weinshenker Neuromyelitis optica in western countries: Establishing diagnostic criteria and characterization of the spectrum , 2008 .

[47]  M. Gotkine Neuromyelitis optica and the Optic Neuritis Treatment Trial. , 2008, Archives of neurology.

[48]  Craig H. Smith Neuromyelitis Optica and the Optic Neuritis Treatment Trial—Reply , 2008 .

[49]  Aaron E Miller,et al.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. , 2008, Archives of neurology.

[50]  J. Kurtzke,et al.  Characteristics of Devic's disease (neuromyelitis optica) in Mexico , 2008, Journal of Neurology.

[51]  Yasuto Itoyama,et al.  Preferential spinal central gray matter involvement in neuromyelitis optica , 2008, Journal of neurology.

[52]  A. Bar-Or,et al.  Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders , 2008, Neurology.

[53]  B. Weinshenker,et al.  The spectrum of neuromyelitis optica , 2007, The Lancet Neurology.

[54]  S. Olindo,et al.  Natural history of the visual impairment of relapsing neuromyelitis optica. , 2007, Ophthalmology.

[55]  Y. Matsumoto,et al.  Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination , 2007, Journal of the Neurological Sciences.

[56]  M. Ramanathan,et al.  Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). , 2006, Archives of neurology.

[57]  B. Weinshenker,et al.  Revised diagnostic criteria for neuromyelitis optica , 2006, Neurology.

[58]  L. Balcer Clinical practice. Optic neuritis. , 2006, The New England journal of medicine.

[59]  Y. Itoyama,et al.  Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica , 2005, Neurology.

[60]  A. Bar-Or,et al.  Neuromyelitis optica with hypothalamic involvement , 2005, Multiple sclerosis.

[61]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[62]  A. Ghezzi,et al.  Devic’s neuromyelitis optica: clinical features and prognostic factors , 2004, Neurological Sciences.

[63]  A. Verier,et al.  Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile , 2002, Journal of the Neurological Sciences.

[64]  P. Cabre,et al.  MS and neuromyelitis optica in Martinique (French West Indies) , 2001, Neurology.

[65]  A. Minagar,et al.  Treatment of Devic's Disease with Methotrexate and Prednisone , 2000 .

[66]  B. Weinshenker,et al.  A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease , 1999, Annals of neurology.

[67]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[68]  R. Mandler,et al.  Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine , 1998, Neurology.

[69]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .

[70]  Popescu B. F. Gh.,et al.  視神経脊髄炎のユニークな最後野病変: 悪心,嘔吐,および病理発症の意味 , 2011 .

[71]  J. Leavitt NMO-IgG detected in CSF in seronegative neuromyelitis optica , 2010 .

[72]  Patrick Vermersch,et al.  Neuromyelitis optica and non organ-specific autoimmunity. , 2008, Archives of neurology.

[73]  M. Nakamura M. D.,et al.  Preferential spinal central gray matter involvement in neuromyelitis optica , 2008, Journal of Neurology.

[74]  L. Thuler,et al.  Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. , 2008, Archives of ophthalmology.

[75]  Massimo Filippi,et al.  Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica , 2004, Journal of Neurology.

[76]  D. Goodin,et al.  Neuromyelitis Optica , 2002, Seminars in neurology.